10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Keap1 Polyclonal Antibody

Catalog # AP73401

Product Information

Application	WB, IHC-P, IF, ICC, E
Primary Accession	Q14145
Reactivity	Human, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Calculated MW	69666

Additional Information

Gene ID	9817
Other Names	KEAP1; INRF2; KIAA0132; KLHL19; Kelch-like ECH-associated protein 1; Cytosolic inhibitor of Nrf2; INrf2; Kelch-like protein 19
Dilution	WB~~Western Blot: 1/500 - 1/2000. IHC-p: 1:100-300 ELISA: 1/20000. Not yet tested in other applications. IHC-P~~Western Blot: 1/500 - 1/2000. IHC-p: 1:100-300 ELISA: 1/20000. Not yet tested in other applications. IF~~1:50~200 ICC~~N/A E~~N/A
Format	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% (W/V) sodium azide.
Storage Conditions	-20℃

Protein Information


Name	KEAP1 {ECO:0000303|PubMed:14585973, ECO:0000312|HGNC:HGNC:23177}
Function	Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex that regulates the response to oxidative stress by targeting NFE2L2/NRF2 for ubiquitination (PubMed:14585973, PubMed:15379550, PubMed:15572695, PubMed:15601839, PubMed:15983046, PubMed:37339955). KEAP1 acts as a key sensor of oxidative and electrophilic stress: in normal conditions, the BCR(KEAP1) complex mediates ubiquitination and degradation of NFE2L2/NRF2, a transcription factor regulating expression of many cytoprotective genes (PubMed:15601839, PubMed:16006525). In response to oxidative stress, different electrophile metabolites trigger non-enzymatic covalent modifications of highly reactive cysteine residues in KEAP1, leading to inactivate the ubiquitin ligase activity of the BCR(KEAP1) complex, promoting NFE2L2/NRF2 nuclear accumulation and expression of phase II detoxifying enzymes (PubMed:16006525, PubMed:17127771, PubMed:18251510, PubMed:19489739, PubMed:29590092). In response to

	selective autophagy, KEAP1 is sequestered in inclusion bodies following its interaction with SQSTM1/p62, leading to inactivation of the BCR(KEAP1) complex and activation of NFE2L2/NRF2 (PubMed:20452972). The BCR(KEAP1) complex also mediates ubiquitination of SQSTM1/p62, increasing SQSTM1/p62 sequestering activity and degradation (PubMed:28380357). The BCR(KEAP1) complex also targets BPTF and PGAM5 for ubiquitination and degradation by the proteasome (PubMed:15379550, PubMed:17046835).
Cellular Location	Cytoplasm. Nucleus. Note=Mainly cytoplasmic (PubMed:15601839). In response to selective autophagy, relocalizes to inclusion bodies following interaction with SQSTM1/p62 (PubMed:20452972).
Tissue Location	Broadly expressed, with highest levels in skeletal muscle.


Background

Acts as a substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1 and targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. Retains NFE2L2/NRF2 and may also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome.


Images




Western Blot analysis of K562 cells using Keap1 Polyclonal Antibody. Antibody was diluted at 1:1000. Secondary antibody was diluted at 1:20000




Immunohistochemical analysis of paraffin-embedded human-skin, antibody was diluted at 1:100



Immunohistochemical analysis of paraffin-embedded human-skin, antibody was diluted at 1:100



Immunohistochemical analysis of paraffin-embedded human-brain, antibody was diluted at 1:100



Immunohistochemical analysis of paraffin-embedded human-brain, antibody was diluted at 1:100

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.